Scholarlink

<p>At ASCO 2025, several promising studies in pancreatic ductal adenocarcinoma (PDAC) were presented. In the neoadjuvant setting, the CASSANDRA trial compared the PAXG (nab-paclitaxel, capecitabine, cisplatin, gemcitabine) chemotherapy regimen with modified (m)FOLFIRINOX (5-fluorouracil +&#xa0;leucovorin, irinotecan, and oxaliplatin), while the NeoPancOne study evaluated the efficacy of mFOLFIRINOX stratified by GATA6 expression. In advanced disease, the phase&#xa0;III PANOVA-3&#xa0;trial investigated tumor treating fields as a&#xa0;novel locoregional therapy. Furthermore, Claudin 18.2 might emerge as a&#xa0;potential biomarker in PDAC, supported by encouraging early-phase data for targeted therapeutic strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

ASCO 2025 highlights: emerging therapies and biomarkers in pancreatic ductal adenocarcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月18日

查看全文
  • Hannes Windhager,
  • Bernhard Doleschal

摘要

At ASCO 2025, several promising studies in pancreatic ductal adenocarcinoma (PDAC) were presented. In the neoadjuvant setting, the CASSANDRA trial compared the PAXG (nab-paclitaxel, capecitabine, cisplatin, gemcitabine) chemotherapy regimen with modified (m)FOLFIRINOX (5-fluorouracil + leucovorin, irinotecan, and oxaliplatin), while the NeoPancOne study evaluated the efficacy of mFOLFIRINOX stratified by GATA6 expression. In advanced disease, the phase III PANOVA-3 trial investigated tumor treating fields as a novel locoregional therapy. Furthermore, Claudin 18.2 might emerge as a potential biomarker in PDAC, supported by encouraging early-phase data for targeted therapeutic strategies.